Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN® to Significantly Reduce Treatment Burden in Patients with Diabetic Macular Edema
13 oct. 2021 08h00 HE
|
Alimera Sciences, Inc.
PALADIN Study Data Presented at the American Society of Retina Specialists Shows That Post-ILUVIEN, the Percentage of Eyes Receiving One Yearly Treatment or Less Increased 3.2-Fold Compared to...
Alimera Sciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
02 sept. 2021 16h30 HE
|
Alimera Sciences, Inc.
ATLANTA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to...
Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN® for DME in Belgium
24 août 2021 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences Announces Second Quarter 2021 Financial Results
13 août 2021 08h00 HE
|
Alimera Sciences, Inc.
Consolidated Net Revenue of $21.7 Million up 117% vs. Second Quarter of 2020Consolidated Net Product Revenue of $10.7 Million up 7% vs. Second Quarter of 2020Net Income of $7.6 Million vs. Net Loss of...
Alimera Sciences to Report Second Quarter 2021 Financial Results on Friday, August 13, 2021, and Provide Corporate Update
10 août 2021 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences and Tanner Pharma Group Initiate Global Named Patient Program for ILUVIEN®
09 août 2021 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences Europe Limited (“Alimera”), a wholly owned subsidiary of Alimera Sciences, Inc., and Tanner Pharma UK Limited (“Tanner”) announced today...
Alimera Sciences, Inc. to Present at the Summer Solstice – Best Ideas from the Buy Side Conference on June 2, 2021
27 mai 2021 08h15 HE
|
Alimera Sciences, Inc.
ATLANTA, May 27, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences Appoints David Dyer, M.D. as Chief Retina Specialist
17 mai 2021 08h12 HE
|
Alimera Sciences, Inc.
ATLANTA, May 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, has announced...
Alimera Sciences Announces First Quarter 2021 Financial Results
28 avr. 2021 16h32 HE
|
Alimera Sciences, Inc.
ATLANTA, April 28, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription...
Alimera Sciences to Report First Quarter 2021 Financial Results on Wednesday, April 28, 2021 and Provide Corporate Update
22 avr. 2021 08h00 HE
|
Alimera Sciences, Inc.
ATLANTA, April 22, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company that specializes in the commercialization and development of prescription...